Details

Last Funding Type

Post-IPO Equity

Last Funding Money Raised

$17.50M

Industries

Biotechnology,Health Care,Manufacturing,Medical Device,Therapeutics

Founded date

Jan 1, 1994

Number Of Employee

51 - 100

Operating Status

Active

Stock Symbol

tlv:INCR

Legal Name

InterCure Ltd

InterCure is a medical device company that has developed and patented a technology platform for respiratory-based treatment of cardiovascular and pulmonary diseases.

The Company has incorporated its "Interactive Respiratory-Pacing" technology platform into several product lines, the first two of which offer a new therapeutic class of non-drug treatments for two of the most widespread and costly disease states in the healthcare industry: hypertension and heart failure.

InterCure’s first market-ready product, RESPeRATE, is the only FDA-cleared, medical device clinically proven to lower high blood pressure with no side effects.

InterCure's heart failure product, InTone™ has successfully completed phase 2a efficacy clinical trials and is expected to be launched when it completes the regulatory approval process.

With its outstanding management team, the board of directors and a world-class Scientific Advisory Board, Intercure is poised to become the market leader in patient-focused medical devices that provide non-drug, no-side-effect treatment for some of the world's most prevalent and costly chronic conditions.

InterCure was founded in 1994 and is headquartered in Ra'anana, Israel.

InterCure has acquired 1 organizations. Their most recent acquisition was Canndoc on Sep 4, 2018. They acquired Canndoc for 0.

Date Company Name	Industry	Acquisition Type	Price
Sep 4, 2018 Canndoc	Alternative Medicine	acquisition	—	Detail